A Phase 3 Study of KRX-0502 (Ferric Citrate) for the Treatment of Iron Deficiency Anemia in Adult Subjects With Non-Dialysis Dependent Chronic Kidney Disease

Trial Profile

A Phase 3 Study of KRX-0502 (Ferric Citrate) for the Treatment of Iron Deficiency Anemia in Adult Subjects With Non-Dialysis Dependent Chronic Kidney Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs Ferric citrate (Primary)
  • Indications Iron deficiency anaemia
  • Focus Therapeutic Use
  • Sponsors Keryx Biopharmaceuticals
  • Most Recent Events

    • 07 Nov 2017 According to Keryx Biopharmaceuticals media release, the U.S. Food and Drug Administration (FDA) has approved Auryxia for the treatment of iron deficiency anemia in adults with chronic kidney disease (CKD), not on dialysis. The sNDA was based on data from this trial.
    • 02 Nov 2017 Results published in the Keryx Biopharmaceuticals media release.
    • 02 Nov 2017 According to Keryx Biopharmaceuticals media release, post-hoc data from this study is published at the 2017 American Society of Nephrology (ASN) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top